Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH - Get Free Report) passed above its 50 day moving average during trading on Monday . The stock has a 50 day moving average of $9.61 and traded as high as $10.80. Theravance Biopharma shares last traded at $10.75, with a volume of 155,522 shares changing hands.
Wall Street Analysts Forecast Growth
A number of equities research analysts have recently issued reports on TBPH shares. Wall Street Zen raised shares of Theravance Biopharma from a "hold" rating to a "buy" rating in a report on Wednesday, May 14th. HC Wainwright reaffirmed a "buy" rating and issued a $15.00 target price on shares of Theravance Biopharma in a report on Tuesday, February 25th. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to data from MarketBeat.com, Theravance Biopharma has a consensus rating of "Hold" and an average target price of $11.33.
Get Our Latest Analysis on Theravance Biopharma
Theravance Biopharma Stock Performance
The stock has a market capitalization of $537.51 million, a P/E ratio of -10.64 and a beta of -0.09. The company's fifty day simple moving average is $9.61 and its two-hundred day simple moving average is $9.45.
Theravance Biopharma (NASDAQ:TBPH - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.16). The company had revenue of $15.39 million during the quarter, compared to the consensus estimate of $28.08 million. Theravance Biopharma had a negative net margin of 78.18% and a negative return on equity of 24.79%. On average, research analysts predict that Theravance Biopharma, Inc. will post -1.09 earnings per share for the current fiscal year.
Insider Buying and Selling
In other news, SVP Rhonda Farnum sold 24,000 shares of the firm's stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $11.00, for a total transaction of $264,000.00. Following the transaction, the senior vice president now directly owns 336,918 shares of the company's stock, valued at approximately $3,706,098. This trade represents a 6.65% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 6.90% of the stock is owned by insiders.
Institutional Inflows and Outflows
Hedge funds have recently made changes to their positions in the business. Aquatic Capital Management LLC bought a new position in shares of Theravance Biopharma during the fourth quarter worth approximately $25,000. GAMMA Investing LLC increased its holdings in shares of Theravance Biopharma by 1,201.8% during the first quarter. GAMMA Investing LLC now owns 3,554 shares of the biopharmaceutical company's stock worth $32,000 after purchasing an additional 3,281 shares during the period. KLP Kapitalforvaltning AS bought a new position in shares of Theravance Biopharma during the fourth quarter worth approximately $69,000. Teacher Retirement System of Texas bought a new position in shares of Theravance Biopharma during the fourth quarter worth approximately $103,000. Finally, AQR Capital Management LLC bought a new position in shares of Theravance Biopharma during the first quarter worth approximately $101,000. 99.10% of the stock is owned by institutional investors.
Theravance Biopharma Company Profile
(
Get Free Report)
Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Theravance Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Theravance Biopharma wasn't on the list.
While Theravance Biopharma currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
